H.C. Wainwright Remains Bullish on Corcept Therapeutics Incorporated (CORT)

Corcept Therapeutics Incorporated (NASDAQ:CORT) is one of the most profitable biotech stocks to invest in now. On July 14, H.C. Wainwright analyst Swayampakula Ramakanth maintained a Buy rating on Corcept Therapeutics Incorporated (NASDAQ:CORT) and set a price target of $145.00.

Why Corcept Therapeutics Incorporated (CORT) Crashed On Monday

A biologist in a lab coat studying a culture of cells to find a cure for metabolic disorders.

Corcept Therapeutics Incorporated (NASDAQ:CORT) reported $157.2 million in revenue in fiscal Q1 2025 compared to $146.8 million in the same quarter last year.

Net income per common share (diluted) for the quarter was $0.17, compared to $0.25 in Q1 2024. The company also reiterated its 2025 revenue guidance of $900 million to $950 million.

Corcept Therapeutics Incorporated (NASDAQ:CORT) is a biopharmaceutical company that develops and commercializes therapies that adjust the effects of cortisol, a hormone that regulates various bodily functions.

The company’s flagship product, Korlym, is FDA-approved for treating Cushing’s syndrome, a disorder caused by excessive cortisol production.

While we acknowledge the potential of CORT to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than CORT and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.